Tagrisso plus chemo improved PFS in lung cancer
17 May 2023 Tagrisso plus chemotherapy demonstrated strong improvement in progression-free survival for patients with EGFR-mutatedadvanced lung cancer in FLAURA2 Phase III trial Results support potential for a new treatment option that builds onthe benefit of first-line standard of care Tagrisso monotherapy Positive high-level results from the FLAURA2 Phase III trial showed AstraZeneca's Tagrisso (osimertinib) in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to Tagrisso